Noninvasive gamma flicker to help Alzheimer’s disease pathways in a female-model study
Official title: Noninvasive Neurostimulation to Reduce Pathology in a Female Mouse Model of Alzheimer's Disease
Funded at Veterans Health Administration · NIH-11381368 · Data updated 2026-11-12
A research project tests a noninvasive light/sound therapy to potentially slow Alzheimer’s-related brain changes in a female mouse model that mimics human disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Decatur, UNITED STATES) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| NIH project number | 5IK2RX004544-04 |
| Project ID | NIH-11381368 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for or in early stages of Alzheimer’s disease who could participate in future trials or benefit from noninvasive neuromodulation therapies.
✕Less likely to help
Patients with advanced Alzheimer’s disease or conditions that contraindicate neuromodulation may not benefit from this line of research.
What this research studies
This project uses a gamma-frequency (40Hz) neuromodulation approach to stimulate brain activity in regions linked to memory, aiming to influence microglia and inflammatory signals and support brain plasticity. The study focuses on sex as a key factor, recognizing that women are more affected by Alzheimer’s and that therapies may work differently in females. Findings from this mouse model could guide future human trials if the approach shows promise in reversing or mitigating pathology and cognitive decline. The research team will examine how gamma flicker interacts with brain chemicals and immune responses that are involved in Alzheimer’s disease.
Why it matters
Potential benefit: If successful, this approach could lead to new, noninvasive treatments that slow or alter Alzheimer’s progression in humans, especially women.
How similar studies have gone: Prior animal studies showed gamma flicker can affect immune and neural pathways linked to Alzheimer’s, but human translation is still being explored.
Where this research is happening
-
Veterans Health Administration
Decatur, United States Active
Researchers
- Principal investigator: Prichard, Ashley — Veterans Health Administration
- Study coordinator: Prichard, Ashley
Related research
Other NIH-funded projects on the same topics.
-
How X chromosome genes may increase Alzheimer's risk in women
Researchers are looking at genes on the X chromosome to learn how they might raise tau and Alzheimer's risk specifically in women.
-
Noninvasive 40Hz light-and-sound brain stimulation aimed at Alzheimer’s changes with a female focus
Seeing if gentle 40Hz light-and-sound stimulation can reduce Alzheimer’s-related brain changes that may be especially important for women.
-
Using noninvasive brain stimulation to improve Alzheimer's disease in female mice
This study is looking at how a gentle light and sound treatment might help improve memory and learning in female mice with Alzheimer's, and it aims to find better ways to treat the disease by focusing on how it affects females differently.
-
Investigating how sex genes affect women's risk of Alzheimer's disease
This study is looking into why women might be more at risk for Alzheimer's disease than men, focusing on how certain genes on the X chromosome and hormones could play a role, with the goal of finding new ways to prevent and treat Alzheimer's in women.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.